Pacific Biosciences (PACB) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic focus and execution

• Emphasis on execution rather than major strategic shifts, targeting clinical markets such as germline genomics, carrier screening, and rare disease diagnostics.

• Recent restructuring aims to reduce cash burn by $40 million, with a focus on stabilizing commercial and R&D teams.

• Prioritizing the rollout and adoption of SPRQ-Nx reagents, which enable multi-use chips and improved economics.

• High throughput platform development remains a top R&D priority, with no plans to add unrelated projects.

• Capital deployment is focused on optimizing manufacturing and supporting the high throughput platform.

Product innovation and market adoption

• SPRQ-Nx reagents allow chip reuse, lowering list prices by 30% and driving new customer projects and fleet expansions.

• Transition to SPRQ-Nx is expected to take two quarters, with revenue and pull-through per instrument recovering by year-end.

• Early customer feedback is positive, with some workflow adjustments needed for optimal third-run yields.

• The multi-use chip breakthrough is seen as transformative for gross margin and long-term sustainability.

• No significant barriers to adoption; focus is on supporting clinical labs through their validation and commercialization processes.

Clinical and geographic expansion

• Europe is leading in adopting whole genome sequencing as a frontline test for rare diseases, with the U.S. focusing initially on carrier screening and targeted panels.

• Success in Europe is expected to be replicated globally as higher throughput and economics improve.

• Clinical consumables growth of 50%+ over the next few years is a key indicator of success.

• Biopharma and AI-driven therapeutic companies are emerging as important new customer segments.

• Academic and government funding remains uncertain, prompting a shift toward more routine clinical and biopharma revenue streams.